Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Crizotinib is a potent small-molecule inhibitor of ALK tyrosine kinase receptor (anaplastic lymphoma kinase; ALK) and hepatocyte growth factor receptor (HGF receptor, proto-oncogene c-Met). A range of tumors, including subsets of non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma and inflammatory myofibroblastic tumors harbor an ALK rearrangement that leads to oncogenic activation of ALK. Crizotinib has demonstrated preclinical and clinical activity against such malignancies through inhibition of ALK, and patients harboring ALK- rearranged NSCLC have demonstrated high response rates and prolonged progression-free survival in phase I and II studies. In August 2011, crizotinib was approved for the treatment of advanced ALK-positive NSCLC.
University of Colorado School of Medicine, Division of Medical Oncology, Aurora, Colorado 80045, USA.
SourceDrugs of today (Barcelona, Spain : 1998) 48:4 2012 Apr pg 271-82
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
Molecular Targeted Therapy
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-met
Receptor Protein-Tyrosine Kinases
Pub Type(s)Journal Article